Cytokine release syndrome
During the last decade the field of cancer immunotherapy has witnessed impressive
progress. Highly effective immunotherapies such as immune checkpoint inhibition, and T …
progress. Highly effective immunotherapies such as immune checkpoint inhibition, and T …
The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies
The successful outcomes of chimeric antigen receptor (CAR) T-cell therapy in treating
hematologic cancers have increased the previously unprecedented excitement to use this …
hematologic cancers have increased the previously unprecedented excitement to use this …
T cell immunobiology and cytokine storm of COVID‐19
Abstract 2019 coronavirus disease (COVID‐19) presents as a newly recognized pneumonia
and could rapidly progress into acute respiratory distress syndrome which has brought …
and could rapidly progress into acute respiratory distress syndrome which has brought …
The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma
J Wei, Y Liu, C Wang, Y Zhang, C Tong, G Dai… - … and Targeted Therapy, 2020 - nature.com
Chimeric antigen receptor T (CAR T) cell therapy has demonstrated efficacy in the treatment
of haematologic malignancies. However, the accompanying adverse events, the most …
of haematologic malignancies. However, the accompanying adverse events, the most …
Critical care management of chimeric antigen receptor T‐cell therapy recipients
Chimeric antigen receptor (CAR) T‐cell therapy is a promising immunotherapeutic treatment
concept that is changing the treatment approach to hematologic malignancies. The …
concept that is changing the treatment approach to hematologic malignancies. The …
CAR-T cell therapy: mechanism, management, and mitigation of inflammatory toxicities
Engineered T cell therapies such as chimeric antigen receptor (CAR) expressing T cells
(CAR-T cells) have great potential to treat many human diseases; however, inflammatory …
(CAR-T cells) have great potential to treat many human diseases; however, inflammatory …
Induction of a central memory and stem cell memory phenotype in functionally active CD4+ and CD8+ CAR T cells produced in an automated good manufacturing practice …
Relapsed/refractory B-precursor acute lymphoblastic leukemia (pre-B ALL) remains a major
therapeutic challenge. Chimeric antigen receptor (CAR) T cells are promising treatment …
therapeutic challenge. Chimeric antigen receptor (CAR) T cells are promising treatment …
Targeting multiple myeloma with AMG 424, a novel anti-CD38/CD3 bispecific T-cell–recruiting antibody optimized for cytotoxicity and cytokine release
Purpose: Despite advances in the treatment of multiple myeloma, new therapies are needed
to induce more profound clinical responses. T-cell–redirected lysis triggered by bispecific …
to induce more profound clinical responses. T-cell–redirected lysis triggered by bispecific …
Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells
Background Standard-of-care therapies for treating pediatric medulloblastoma have long-
term side effects, even in children who are cured. One emerging modality of cancer therapy …
term side effects, even in children who are cured. One emerging modality of cancer therapy …
In the eye of the storm: immune-mediated toxicities associated with CAR-T cell therapy
JG Borrega, P Gödel, MA Rüger, ÖA Onur… - …, 2019 - journals.lww.com
The success of chimeric antigen receptor (CAR)-T cell therapy with impressive response
rates in hematologic malignancies but also promising data in solid tumors came along with …
rates in hematologic malignancies but also promising data in solid tumors came along with …